Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4663-4674
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4663
Table 1 Distribution of the analyzed clinical-imaging features across pathologic risk categories, mean ± SD
CECT features

Pathologic risk categories
P value
High (n = 213)
Moderated (n = 143)
Low (n = 195)
GenderMale10760890.296
Female10683106
LocationGastric1391361710.000
Non-gastric74724
MorphologyRegular 54941700.000
Irregular1594925
Growth patternEndoluminal3554930.000
Mixed512228
Exophytic1276774
Degree of contrast enhancement in the venous phaseMild (≤ 20 HU) 3020200.424
Moderate (20-40 HU) 1017490
Obvious (≥ 40 HU) 824985
Contrast enhancement pattern during the venous phaseContinuous1981421930.000
Attenuation1512
Calcification Present 2216210.967
Absent191127174
Necrosis Present 15565330.000
Absent5878162
Ulceration Present 532380.000
Absent160120187
Enlarged feeding vesselsPresent 18360140.000
Absent3083181
Lymph nodesPresent 19110.000
Absent194142194
Age59.44 ± 10.4161.39 ± 9.8360.37 ± 9.130.183
Size9.03 ± 4.424.90 ± 1.892.77 ± 1.200.000
Range of tumor enhancement during the arterial phase18.83 ± 17.8114.24 ± 11.5318.45 ± 17.470.004
Range of tumor enhancement during the venous phase41.59 ± 25.7338.97 ± 18.9645.22 ± 25.700.038
Range of tumor enhancement during the delay phase42.73 ± 18.8943.72 ± 17.9747.97 ± 20.270.016